EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma.
A randomized clinical trial was designed by the European Organization for Research on Treatment of Cancer (EORTC) to compare the disease-free interval, the degree of malignancy of recurrence and the 5-year survival rate in stage I papillary carcinoma of the bladder after TUR only, and after TUR followed either by local thiotepa or by local VM 26 chemotherapy.
D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011182:Postoperative Care; D012075:Remission, Spontaneous; D013713:Teniposide / Q000008:administration & dosage / Q000627:therapeutic use*; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D013852:Thiotepa; D013713:Teniposide; D011034:Podophyllotoxin